Market capitalization | $571.38m |
Enterprise Value | $494.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.72 |
P/S ratio (TTM) P/S ratio | 6.60 |
P/B ratio (TTM) P/B ratio | 5.99 |
Revenue growth (TTM) Revenue growth | 1.84% |
Revenue (TTM) Revenue | $86.55m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
10 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
10 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 87 87 |
2%
2%
|
|
Gross Profit | 77 77 |
4%
4%
|
|
EBITDA | -27 -27 |
34%
34%
|
EBIT (Operating Income) EBIT | -28 -28 |
34%
34%
|
Net Profit | -25 -25 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Rossi |
Employees | 100 |
Founded | 2015 |
Website | www.ymabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.